A number of weeds growing around your house are edible. Chickweed (Stellaria media) is found in lawns and random areas in cooler climates. It pops out ahead of most other plants in the spring, though it also grows year-round.
It can grow low, hiding in the grass, but it is easier to harvest as a taller standalone clump. Here is a clump from my yard, with the roots and tougher lower parts cut off:
People eat it raw, but I prefer to blanch it first to reduce any bitterness and to get rid of any critters or contaminants. To do that, I got two cups of water boiling in a Pyrex measuring cup, then dropped the chickweed in and stirred it around for a minute, followed by a cool water quench in a colander. The chickweed was then in a wilted state, but still green and crunchy and (as I understand) retaining nearly all its nutrients.
For me, chickweed functions like arugula or cilantro or Italian parsley, as an interesting and worthwhile addition to a salad or sandwich. I would not relish a whole plate of it.
Speaking of nutrients, in folk medicine chickweed is credited with amazing powers. Eat The Planet tells us that:
Chickweed is full of vitamins A, B1, B2, and C as well as fiber and protein. Due to its nutritional contents and numerous medicinal properties, this cold-weather herb has been used in folk medicine for hundreds of years. It can treat many different conditions, such as constipation, bowel problems, iron-deficiency anemia, asthma, bronchitis, joint pains, and blood disorders. It can also aid weight loss by making you feel fuller for longer.
You can also apply the herb directly onto the skin to treat itchiness, bruises, boils, ulcers, and psoriasis. To do this, you can either bruise the leaves or steep the stems in hot water before applying them directly onto the affected areas.
There is no indication that any of the plant’s constituents possess therapeutic activity. Its vitamin content is too low to be of therapeutic value.
Verywellhealth stakes out a middle ground, noting that chickweed has demonstrated significant anti-inflammatory and anti-viral activity in lab experiments with animals, but also noting that these results may or may not translate to efficacy in humans:
Juice or extracts made from chickweed have been studied in test tubes or mice models for the following conditions:
Hepatitis B. Chickweed was shown to have anti-hepatitis B virus activity in a test tube study.
Obesity. Chickweed extract given to overweight mice decreased the amount of food they consumed and their absorption of fats.
Diabetes. Chickweed leaf extract demonstrated antidiabetic effects, such as lowering blood sugar and hemoglobin A1c in mouse models.
Heart problems in people with diabetes. Chickweed tea given to diabetic rats did not improve their blood sugar levels but did seem to protect against cardiomyopathy.
Anxiety. Chickweed given to mice showed similar activity as diazepam, a classic anxiety medication in the benzodiazepine family.
For what it’s worth, I will pass along a couple of points from an optimistic take on the current stock market pullback, by Seeking Alpha author Dividend Sensei. The article is “History Says Shut Up And Buy: 12 Hyper-Growth Blue Chips To Buy Right Now”. His thesis is that corrections come and go as specific fears come and go, but tech stocks only keep going up, so now is a good time to buy.
History seems to be on his side. Below is a 25-year plot of the NASDAQ 100 fund QQQ. It is true that on a really long scale, any significant dip would have been a good buying opportunity. And the run-up since 2016 has been astonishing. $10,000 invested then would be about $50,000 now. I find it sobering, however, that (just going by eyeball) it took about fourteen years for QQQ to regain its 2000 peak. That might be longer than most investors want to wait. And in the shorter term, these tech stocks lost some 80% of their market value between 2000 and 2002, and revisited that low in 2008. We can look back now from decades later and call this a “dip”, but at the time it felt like an endless investment nightmare.
(I should add that the 2000 peak pricing was not supported by appreciable cash earnings, but by breathless hype about this new thing called the “internet” that was going to change EVERYTHING. This past year has seen similar hyperventilation over AI, but in contrast to 2000, now the big tech firms make ginormous gobs of money, and gobs more each year. So maybe it really is different this time…)
QQQ total return since March 1, 1999; % scale. From Seeking Alpha.
The Psychology of Market Corrections
The author pointed out that every correction is based on some deep fear, and eventually that fear dissipates. I thought this table he showed of the fear factors involved in the 30 or so stock market pullbacks since the March 2009 low was interesting and instructive:
The type here may be hard to read, so I will repeat here the two most recent “fears” listed, both from 2024:
March 28-Apr 19 (5.9% drop): “Stubborn Inflation, Fed Pushing Back Rate Cuts, Iran/Israel Conflict”
These are recent enough that any market-engaged reader here will resonate with these concerns which loomed so large at the time. And yet, the collective market shrugged them all off to post a robust 21% gain for all of 2024.
Where do we go from here? I have no idea. As of writing this Tuesday morning, we seem to be bumping along at a level 2-3% higher in QQQ than the lows last week, but still 10-11 % lower than a month ago. This has brought it to levels of about late September, 2024. If I look at a five-year log plot and draw an eyeball-fit straight line through it all, it seems like prices went above that line for Nov-early Feb, in a burst of post-election enthusiasm, but have now come back to the trendline. Barring some macro or geopolitical disaster, therefore, one might expect QQQ to trend 10-15 % higher in the next twelve months (with a standard deviation of another 10% or so around the trendline). But as old-time Yankees catcher Yogi Berra said, “It’s tough to make predictions, especially about the future.”
Disclaimer: Nothing here should be considered advice to buy or sell any security.
As of the market open today, tech stocks (e.g. the NASDAQ 100 fund QQQ) are down more than 10% from their recent highs. The broader S&P 500 fund SPY is down about 8%. Hands are wringing…what does it all mean?
By applying standard definitions, we can know exactly what it means:
A pullback is a market drop of 5-10% and is very short term. It is a dip from a recent high during an ongoing bull market while upward momentum is still intact, and is a normal adjustment to a market cycle.
The market is in “correction phase” after a drop between 10-20% and can last a few months. These moves are typically met with higher volatility. Corrections can be violent as investors’ fear levels rise and panic selling may hit the market.
Real time news and social media can intensify this fear as investors may follow the herd mentality. The average market correction lasts anywhere between two and four months and is frequently accompanied by adverse market conditions. However, corrections are often seen as ideal times to buy high-value stocks at discounted prices.
So, technically, the S&P has experienced a “pullback”, while the NASDAQ 100 has undergone a “correction”. Just to round out the infernal trinity of market moves with a definition of a “bear market”:
A bear market occurs after a drop of 20+% over at least a two-month time frame. In a bear market, investor confidence has been shattered and many investors will sell their stocks for fear of further losses. Trading activity tends to decrease as do dividend yields.
Bear markets tend to become vicious cycles when rallies are sold and not bought This happened in 2000 and 2007 and can typically be seen on charts as the market makes lower lows and lower highs. Bear markets tend to occur in the contraction phase of the business cycle and last, on average, approximately 16 months.
You don’t know if you are really in a bear market until things get really bad, at which point it is probably too late to sell. (Amateurs get discouraged and sell AFTER stocks have dropped, which is why the average investor does appreciably worse than the accounts of dead people where stocks just sit there without being traded). When stocks recover at least 20% following a bear market over at least a two-month period, that is defined as the start of a new bull market regime.
Having a correction (i.e. 10-20% dip) in the middle of a bull market year is pretty normal. Although whole-year market returns have been positive for 34 out of the past 45 years, the typical year experiences a correction averaging 14%.
None of this vocabulary clarification answers the practical question of how bad will the current pullback/correction get? As usual, I read argument on both sides. The bears are saying (a) what they have been saying since 2018 or so, that the market is unrealistically overvalued, and (b) the macroeconomic world is about to fall apart, which they have also been saying for years. This time may be different, with the new administration’s erratic policies, but history shows that so far, the market is not much correlated to who is in the West Wing.
The bulls are saying (a) the market values did get run up unrealistically after the election and with AI hype, so the current pullback is just a healthy reset to a level for resuming further market growth, and (b) despite negative talking, the actual numbers show decent employment and GDP, so macro is OK (and it is very rare to have an actual bear market absent a serious bad macroeconomic driver).
If I really knew the answer here, I would be writing this from my private Caribbean island. But I’ll share how I am playing it. For the past 15 years or so, it has nearly always worked well to buy in after a say 10% correction. What seemed so gut-wrenching and scary at the time almost always turns into just a blip on the endlessly rising market charts in hindsight.
I had set aside some “dry powder” funds specifically to take advantage of buying opportunities like now. So, I am manfully mastering my fears and buying small amounts every couple days of 2X levered funds like SSO and QLD. (See here for discussion of such funds, they go up or down $2 for every $1 the underlying S&P or NASDAQ go up or down, so it’s kind of like being able to buy twice as much stock for the same dollar amount. But as usual, caveat emptor).
But I am not going all-in on any particular day. It is always frustrating to miss buying right at the bottom, but nobody rings a bell there, either. I have searing memories of March 2020 and of 2008 when just when you thought the bottom was in, it dropped out the next day or week.
Disclaimer: Nothing here should be considered advice to buy or sell any security.
Since I have posted on the recreational drugs/painkillers kava and kratom for the past two weeks (here and here), I figured I would round it out with a look at the various active compounds that can be derived from the cannabis plant. I knew of THC (the main psychoactive ingredient in weed) and CBD (very tame), but there are many others. When I visited that head shop/kava bar in Florida last month, I noted that they sold a lot of products containing THC-A, THC-P, and HHC, since THC sale is illegal there:
“Super Looper” Vapes, Containing Cannabinoids
The stork clerk showed me the following road-map (with its color-coded “Measure Your Mellow” legend) of various cannabinoids, taking you from innocuous CBD (“Non-psychoactive, soothes anxiety, anti-inflammatory; calming, relaxing”) to THC-P (“Very psychoactive, best entourage effect; energizing, euphoric, total head and body high”) and HHC-P (“Strongest and longest-lasting psychoactive effect; energizing, sativa-like effect”):
Road-Map of Cannabinoids, with putative effects.
On this roadmap, the main “THC” ingredient in weed is shown as Delta-9 or trans-delta-9-Tetrahydrocannabinol (rated as “Very Psychoactive”).
I don’t want to go too far down this rabbit-hole, but out of curiosity I looked up a few articles to try to understand this zoo of mind-altering compounds. Out of sheer laziness, I’ll start with Wikipedia’s take on the pharmacology, focusing on THC itself:
When THC enters the blood stream and reaches the brain, it binds to cannabinoid receptors. The endogenous ligand of these receptors is anandamide, the effects of which THC emulates. This agonism of the cannabinoid receptors results in changes in the levels of various neurotransmitters, especially dopamine and norepinephrine, which are closely associated with the acute effects of cannabis ingestion, such as euphoria and anxiety. Some effects may include a general altered state of consciousness, euphoria, relaxation or stress reduction, increased appreciation of the arts, including humor and music, joviality, metacognition and introspection, enhanced recollection (episodic memory), and increased sensuality, sensory awareness, libido, and creativity. Abstract or philosophical thinking, disruption of linear memory and paranoia or anxiety are also typical. Anxiety is cannabis’s most commonly reported adverse side effect. Up to 30 percent of recreational users experience intense anxiety and/or panic attacks after smoking cannabis….Cannabidiol (CBD), another cannabinoid found in cannabis, has been shown to mitigate THC’s adverse effects, including anxiety.
Cannabis produces many other subjective effects, including increased enjoyment of food taste and aroma, and marked distortions in the perception of time. At higher doses, effects can include altered body image, auditory or visual illusions, pseudohallucinations, and ataxia from selective impairment of polysynaptic reflexes. In some cases, cannabis can lead to acute psychosis and dissociative states such as depersonalization and derealization.
Regarding some other cannabinoids:
There are similar compounds in cannabis that do not exhibit psychoactive response but are obligatory for functionality: cannabidiol (CBD), an isomer of THC; cannabivarin (CBV), an analog of cannabinol (CBN) with a different side chain, cannabidivarin (CBDV), an analog of CBD with a different side chain, and cannabinolic acid. CBD is believed to regulate the metabolism of THC by inactivating cytochrome P450 enzymes that metabolize drugs; one such mechanism is via generation of carbon monoxide (a pharmacologically active neurotransmitter) by upon metabolism of CBD.[14] THC is converted rapidly to 11-hydroxy-THC, which is also pharmacologically active, so the euphoria outlasts measurable THC levels in blood.
Almost none of these psychoactive compounds are present in the raw cannabis plant. The raw plant contains THC-A, which is then converted to THC and CBD, etc., by heating (e.g. by the heat of burning the dried leaves in a joint, or by baking in brownies). THC-A itself seems to have some attractive anti-inflammatory properties. This NIH article has a listing of the major classes of cannabinoids along with a description of their chemistries. Various synthetic cannabinoids have also been created, with some them now included in pharmaceutical preparations. I have not dug into all the research, but it seems likely to me that some combination of these other cannabinoids might have more favorable effects than plain old THC.
Although CBD is not itself psychoactive, it appears to helpfully modulate the effects of THC, and to have its own useful properties. It is used to treat seizures, and possibly anxiety and chronic pain. It can be eaten (think: gummy bears) or applied in skin patches (for longest-lasting, controlled exposure) or oils or lotions. Some varieties (e.g. “Full-Spectrum”) of CBD contain traces of THC, and so act more strongly.
Taking cannabinoids via a tincture under the tongue (where it can cross a mucous membrane, into the bloodstream) takes longer than smoking to show effects, but they last longer. It also gives a more precise dosage, and avoids smoke inhalation, so this seems like a preferable route if it is available. I recall reading some months back that a mixture of THC and CBD taken sublingually was effective in controlling pain. Eating cannabis, as in “Colorado” brownies, can be problematic: it often takes several hours to take effect (via liver metabolism), so users get impatient and start eating more brownies, and then end up way higher than intended.
Long-term adverse effects of cannabis are controversial. Some researchers claim there are none, but:
There is evidence that long-term use of cannabis increases the risk of psychosis, regardless of confounding factors, and particularly for people who have genetic risk factors. A 2019 meta-analysis found that 34% of people with cannabis-induced psychosis transitioned to schizophrenia. This was found to be comparatively higher than hallucinogens (26%) and amphetamines (22%).
Long-term cannabis users are at risk for developing cannabinoid hyperemesis syndrome (CHS), characterized by recurrent bouts of intense vomiting and abdominal cramping during or within 48 hours of heavy cannabis use.
Also, a very recent large study found that 63% of long-term heavy cannabis users had significantly reduced brain function for working memory tasks. (I’ll add that I know someone whose trajectory very strongly suggests that exposure to weed in early teens put a permanent crimp in her mental and emotional functioning).
It seems that habitual use of cannabis can result in general “chill” lassitude, which lowers productivity. As one counselor told a friend of mine, “It is true that with weed ‘nothing happens.’ That is just the problem.”
Weed has long been touted as an alternative pain-killer. I know of people who claim benefits here. Most states allow “medical marijuana” for conditions such as chronic pain or nausea. However, its use is still unlawful at the federal level, so weed must be grown in-state and not transported across state lines.
This NIH site summarizes many studies on cannabis for pain. The evidence is very mixed. Often a significant fraction of subjects report improvements, but so do those on placebos.
My totally amateur takeaway from this flyover: THC and related cannabinoids have a variety of effects on the mind, mostly pleasant but sometimes bad or very bad. There seems little evidence for adverse effects of weed on the body (outside of the brain), but real dangers of messing up your brain with heavy or extended use. As usual with these recreational drugs, harmful interactions are very likely if other substances are used at the same time.
As for pain treatment, it’s effectiveness seems to vary a lot among individuals. Weed may be worth a try as an alternative to opioids, but it still carries significant dangers
If I had to pick a poison for myself as alternative painkiller, at this point it would be a tie between weed (which messes with your brain, not so much your body), and kava (whose side effects mainly show in body parts like the liver and the skin, plus brief nausea). I would experiment to see what worked for me. But first I would make every effort to treat pain through some other means. There are many possible treatments for pain which may be safer than cannabis, and new treatments keep coming. For instance, a friend with neuropathy told me that he experienced relief with a new medicine called Neuropaway.
Huge Disclaimer: I have no expert knowledge here. Don’t act on anything here. All I have done is summarize a few articles. Consult your doctor before doing anything.
P.S.
I could not resist taking a look at the side-effects of drinking alcohol. After all, we all do it, and we have all seen headlines claiming health benefits of drinking a glass of red wine a day. Well, the medical community is pretty down on drinking, saying the proven harms far outweigh the few, slight proven benefits. Even “moderate” consumption can overtax the liver, which really damages it, per this.
This article was updated on March 1 with additional information on kava side effects.
This is a follow-up to my post last week, describing my visit to a shop purveying beverages laced with kava and with kratom, two substances I had not heard of previously. As a service to readers who may deal with someone who is using these materials, here is what I have found out about what they do to people.
Upfront disclaimer: I have no expertise in this area, these are just the observations of an amateur who has read a few articles. Do not make any decisions based on this article.
Primary Effects of Kava
Kava is made from the roots of a plant in the pepper family, which is native to the Pacific Islands. There are two main classes of kava plants. The “noble” cultivars are what has traditionally been used for human consumption, via water extraction of the roots to make a beverage. The non-noble (two-day or “tudei”) cultivars grow faster (so they are cheaper for production), but are more likely to have adverse side effects. Also, the above-ground parts of the plants are known to contain toxic alkaloids.
The Wikipedia summary of effects is, “Systematic reviews and meta-analyses conducted in the last decade have typically indicated a modest positive effect of kava on anxiety and generalized anxiety disorder, though the evidence is mixed and further research is frequently recommended.”
I found a 2020 memo by a FDA toxicologist, titled “Review of the published literature pertaining to the safety of Kava for use in conventional foods”, which covers both the positive effects and the extensive side-effects. The memo notes: “The major physiological action in humans is consistently reported as a pleasant, mild, centrally acting relaxant property which induces a generalized muscle relaxation and, ultimately, a deep natural sleep. A minor property of kava is its local anesthetic properties which are experienced as numbing of the mucous membranes of the mouth and tongue when the beverage is consumed.” That all sounds pretty nice.
The main active compounds in cava are called kavalactones. Known effects of the six major kavalactones are:
For the biochemists among us: “The psychotropic effects of kava are achieved by the modulation of gamma‐amino‐butyric acid (GABA) receptors. Although the exact mechanisms are not known, studies suggest that the effects are mediated via different mechanisms such as upregulation of GABA‐A receptor function, blockade of voltage‐gated sodium ion channels, enhanced ligand binding across GABA‐A receptor subtypes, and reduced excitatory neurotransmitter release.” GABA is the primary inhibitory neurotransmitter in the central nervous system, so it is commonly targeted by tranquilizers such as benzodiazepines (e.g. Valium). Hence, the calming effect. Research suggests that kava components also inhibit the re-uptake of norepinephrine (a chemical that makes you feel alert) and of dopamine (a feel-good hormone).
Side Effects of Kava
The most controversial issue is liver damage. There were a number of very severe cases (complete liver failure) in the late 1990s/early 2000s in Europe, which led to a ban of kava in a number of countries there starting around 2002. It was not banned in the U.S., but the FDA issued an advisory letter expressing concern about liver damage.
Kava advocates were unconvinced, and further research seems to indicate that nearly all of those liver damage cases were due to use of the non-noble cultivars and/or the use of stems instead of just the roots and/or the extraction being done with some alcoholic solvent rather than water (probably due to greedy/ignorant kava suppliers). Most European countries have relaxed their outright bans, although in many cases kava sales are still restricted or regulated. Because their main market got shut off due to the liver problems, Pacific island nations scrambled to rebuild kava credibility. They now try to ensure that only proper kava is exported to the West.
Kava advocates claim that if kava is extracted the traditional way from traditional cultivars, there are no appreciable severe bad side-effects. On the other hand, the 2020 FDA memo document claimed there was a wide range of serious adverse effects of kava use among traditional kava users in the eastern Pacific, especially liver damage, among heavy kava drinkers: “Several studies show a clear association of increased level of liver enzymes GGT, ALP, and moderate to heavy kava beverage consumption as shown in Table 2…..Hepatic injury due to traditional aqueous extracts of kava root was reported in a study of 27 heavy kava drinkers in New Caledonia (Russmann et al. 2003).”
On closer examination, however, it seems that the FDA document gave an overly negative view of kava liver effects. The Russman 2003 study did not actually show “heptatic injury” among the 27 heavy kava drinkers. All it showed was elevated levels of the liver-related enzymes. It is true that there were pretty consistent observations of elevated levels of enzymes such as GGT (gamma-glutamyl transpeptidase) and ALP (alanine aminotransferase) in blood samples. Most of the studies of Polynesian subjects cited in the FDA memo lacked controls, but Brown (2007) included kava users and nonusers in its survey of Tongans living in Hawaii. This study showed high levels of GGT and ALP among the kava users, yet without any clinical indications of liver malfunction. Also, other liver-related markers in the blood such as AST, ALT, bilirubin, and ferritin were normal in the kava users. The significance of the partial abnormalities in enzymes is not clear. My guess is that the liver is somewhat stressed but not to the point of malfunction.
So it seems true that moderate consumption of kava prepared the traditional way (water extraction from roots of noble cultivars) shows no general tendency for observable liver damage. That said, the elevated liver-related enzymes are grounds for at least a little caution, and there have been a (very) few cases of genuine liver damage from traditionally extracted kava. Russman (2003) reported two women in New Caledonia who developed symptoms of liver distress from kava; these symptoms resolved after cessation of kava use. And Becker (2019) documented the case of an otherwise healthy woman in Brazil who experienced complete liver failure following 52 days of using an approved kava pill at approved dosage; her life was saved by a liver transplant. However, people die every year from eating peanuts, so I don’t know how much to read into these isolated cases of liver damage from kava.
A common effect of kava use is dermatitis, presenting as dry skin, rashes, and eruptions. (This strikes me as an allergic-type reaction). Other common side-effects can be nausea and headaches. These effects typically resolve quickly if kava use is discontinued. In the plus column, there is some sketchy evidence for anti-cancer activity by kava. In general, cognition is not impaired.
I read about sixty reviews on Amazon from purchasers of kava root powders, and more discussions on Reddit. Most were quite happy with the kava products, but emphasized that preparing the drink from the root takes some time and effort to squeeze and then filter; the brew tastes terrible, like dirt (you have to gulp it down, not sip it), and some temporary nausea is common. However, there were a nontrivial minority that reported very ugly experiences, and one man who with his first dose went comatose and nearly died. The general opinion is that kava beverage made fresh (by you or at a kava bar) from the ground root is better than capsules or packaged drinks made from kava extracts.
The exact effects may depend on your genome – some folks may get whacked, while others escape unscathed. And there may be systemic differences between how Caucasians and Polynesians react to kava. Apparently you must chug it down on an empty stomach to get the full effects. It is best to drink it in multiple small increments, rather than one giant glass. Some users chase each “shell” with a swish of some other beverage to clear the taste out, and/or eat a tiny snack like a few chips to calm the queasy stomach.
Side effects seem to be greatly amplified when kava is consumed with other substances, especially alcohol. That makes chemical sense, since kava acts on many of the same metabolic pathways as alcohol and antianxiety meds like benzodiazepines and barbiturates. This is significant, since in the West kava is often consumed in a social context which includes alcohol.
For further reading on kava effects: see an objective 2022 review by Soarez, and many pro-kava articles such as this on the kava promotion site kavacoalition.org. That site includes testimonials of people using kava instead of opioids for coping with chronic pain from injuries. Although its main function is to reduce anxiety, that in turn may mitigate the sensations of pain. A number of participants in a Reddit thread stated that kava has helped them overcome alcoholism.
One source estimated that there are about 200 kava bars in the U.S., with about half of them in Florida. After a court battle with the state, a kava bar opened in Virginia in 2024. The state has so far has not approved serving of kratom.
My takeaway on kava: It seems to me to be somewhat similar to cannabis or alcohol – light, occasional use can give a good feeling, especially pleasant as a shared experience with friends. For some, it might be helpful in coping with pain. Unlike alcohol, there seems to be no obvious tendency towards addiction. However, as with alcohol and cannabis, there is some possibility of serious adverse effects, especially with heavy use and if it is consumed with other substances. Therefore, it would seem wise to start slow with kava and monitor your body’s reactions.
Also, it is essential to make sure you are getting kava made the right way, as discussed above. At a kava bar, you can talk with the server. If you are taking capsules, I’d suggest contacting the manufacturer. Or you can buy plain kava root, and steep your own brew.
Effects of Kratom
I will spend less time on kratom effects, since it acts largely like an opioid. Need we say more.
Kratom is extracted from the leaves of an evergreen plant native to southeast Asia. We discussed some of the varieties of kratom earlier. Quotations here are all from the Wikipedia article; they mesh with what I have read elsewhere.
The active compounds are a mix of dozens of alkaloid compounds. The key ones seem to interact with opioid receptors in the brain. But the interactions are complex and poorly-understood. On the plus side, “These compounds display functional selectivity and do not activate the β-arrestin pathway partly responsible for the respiratory depression, constipation, and sedation associated with traditional opioids.”
For recreational use, “At low doses, kratom produces euphoric effects comparable to those of coca. At higher doses, kratom produces opioid-like effects.” Much of kratom use is for more serious issues, such as managing chronic pain or helping with opioid withdrawal.
There are many documented adverse side effects, resulting in many visits to hospitals:
Common side-effects include appetite loss, erectile dysfunction, nausea and constipation. More severe side-effects may include respiratory depression (decreased breathing), seizure, psychosis, elevated heart rate and blood pressure, trouble sleeping, and, rarely, liver toxicity. Addiction is a possible risk with regular use: when use is stopped, withdrawal symptoms may occur. A number of deaths have been attributed to the use of kratom, both by itself and mixed with other substances.
…Long-term use of high doses of kratom may lead to development of tolerance, dependence, and withdrawal symptoms, including loss of appetite, weight loss, decreased libido, insomnia, muscle spasms, muscle and bone pain, increased yawning and/or sneezing, myoclonus, watery eyes, hot flashes, fever, diarrhea, restlessness, anger, and sadness. This may lead to resumption of use. Frequent use of high doses of kratom may cause tremors, anorexia, weight loss, seizures, psychosis and other mental health conditions.
Perhaps the biggest concern with kratom is the high propensity for addiction and the need to increase dosage to obtain the desired effects:
Kratom is a botanical with a known addiction liability and, in vulnerable individuals, dependence may develop rather quickly with tolerance noted at three months and four- to ten-fold dose escalations required within the first few weeks…Kratom addiction carries a relapse risk as high as 78% to 89% at three months post-cessation.
In 2017 the FDA stated that “There is no reliable evidence to support the use of kratom as a treatment for opioid use disorder; there are currently no FDA-approved therapeutic uses of kratom… and the FDA has evidence to show that there are significant safety issues associated with its use.”
Some advice here on Reddit on how with kratom “less is more” — due to complex biochemical interactions, upping your dose or making it more frequent can actually diminish the desired effects, and start down the road of diminishing returns and then using higher and higher doses. And this Reddit where users describe their problems with kratom addiction:
i suggest you stop while you are still able to walk away relatively unscathed. addiction is a very disgusting thing that can happen to a person. you will absolutely feel worse than you ever thought you could feel, save for losing a child or something insane happening IRL.
some drugs will actually cause a physical addiction, like kratom. this means your body adjusts to it & stops doing its job in order to let the drug do it. now when you stop using, your body & mind are without their own processes & they are also without the drug. this leaves you empty, sick, wide awake but exhausted, sweaty but cold, aching pain. for alcohol, withdrawal can actually lead to seizures, extreme hallucinations & delusions, & even will just straight up kill you bc you need a drink so bad.
My takeaway on kratom: This one seems like playing with fire, due to its addictive properties. Also, street doses of kratom are sometimes spiked with horrible drugs like fentanyl. Thus, I see little case for promoting it for recreational use, given that there are safer alternatives such as weed, booze, and kava. (And in general, there are more fruitful ways to rise above anxiety than drinking or smoking something – – change your thinking patterns, or even use flashing lights to put your brain into alpha waves. )
It is possible that kratom could be useful to someone dealing with chronic pain, as an alternative to opioids with their known addition danger. I have deep sympathy for anyone in that position. I would hope that they would work with a medical professional or at least a trustworthy friend to monitor their usage (keeping it low, no matter what), since in these matters it is easy to deceive oneself as to what is really going on.
ADDENDUM
In case someone is tempted to try kratom out of curiosity, I will share the cautionary observation an acquaintance emailed me after reading the original version of this article:
You know, I met some heroin addicts who said that they always told themselves they wouldn’t do it, they had seen it destroy people. But they ended up one day just caving to curiosity. One day, they just shrugged and said “screw it, I wanna see what this is about.” And their life was ruined by the immediate addiction. It’s a very sad story.
Last week I visited a family member in Saint Petersburg, Florida. We had a very nice time, walking around the pier area of the city and going out on his boat. Every day was the same weather: sunny, and a high of 80° F (in mid-February).
I was out walking in the neighborhood, and I saw signage for a shop that piqued my curiosity. It offered cannabis products, which I knew about, but also “kava” and “kratom”, and apparently “nitro”. When I came back to the house, I asked my host what kava was. He indicated it was some kind of recreational drug, whose use seemed to be expanding, at least in that area. I did a superficial check online, finding that kava is an extract from the roots of a plant native to some South Pacific islands, which is reputed to have anxiety-reducing and other feel-good properties.
A couple of days later I walked into the shop and introduced myself as an out-of-state tourist, who saw the sign out front and was curious. There were no other customers at the time, so the saleswoman patiently graciously answered my questions.
I started off asking about kava. But she indicated there was actually more interest in kratom. That is what she imbibes herself, although not frequently. Kratom is extracted from the leaves of an evergreen, Mitragyna speciosa, which is native to Southeast Asia. It seems to have stronger effects than kava, and a physician I spoke with felt that kratom was more likely to be addictive. (I plan to do a deeper dive into the pharmacology of kava and kratom in later articles on this blog).
I was told that kratom comes in three main types: red, green, and white. These are extracted at different stages of leaf maturity. Red is for pain relief, white is for energy, and green is in between. “Train wreck” has all three colors. The products in the shop with kratom, or kratom plus kava greatly outnumbered those with kava alone.
For pure kava, I would have to buy a can of soda (photo below) or buy a prepared drink at the bar.
While we were there, a customer came and ordered two drinks from the bar. He was a middle-aged, upstanding citizen, not some alienated youth covered in tattoos and body-piercings. He told us he has been using kratom for two weeks now, and it has helped him considerably. He said he suffers pain from arthritis and from operations, and that his alcohol use has gone way down since he started kratom. Normally, this man uses white kratom, but since the bar was out of the white extract, he walked out with two large cups of “train wreck”.
The shop also sells various cannabis related products. They mainly contain THCA, which is a legal and less potent version of THC, which is the most active ingredient in marijuana.
The sign out front offered mushrooms as well; I am not sure how “magic” they are. As for “nitro”, it turns out that that is not another psychotropic drug. It is just cold-brewed coffee infused with nitrogen gas, to give a somewhat creamy emulsion. Just another way for Americans to spend $6.00 on a cup of coffee.
I thought about buying and trying some kava or kratom drink, for the sake of science, but at my age I figured I needed to keep all my brain cells. I recalled that decades ago it was emphatically stated that marijuana (unlike alcohol) was not harmful, but now we know better. So, I thanked the clerk and walked out empty-handed.
POST-SCRIPT: See my follow-up article on effects of kava and kratom. Kava seems fairly safe and pleasant, maybe on a par with weed, but kratom functions largely like an opioid and should probably be avoided. Also, based on my additional reading, the kava beverages depicted above are likely to be ineffective; the way to go is to fresh-squeeze ground-up kava root in water. This can be done by you, or for you at a kava bar.
The left-hand side shows that there is very little correlation between the current forward P/E ratio and the returns in the next year; as we have seen in the past few years, and canonically in say 1995-1999, market euphoria can commonly carry over from one year to the next. (See here for discussion of momentum effect in stock prices). So, on this basis, the current sky-high P/E should give us no concern about returns in the next year.
However, the right-hand side is sobering. It shows a very strong tendency for poor ten-year returns if the current P/E is high. In fact, this chart suggests a ten-year return of near zero, starting with the current market pricing. Various financial institutions are likewise forecasting a decade of muted returns [1].
The classic optimistic-but-naïve response to unwelcome facts like these is to argue, “But this time it’s different.” I am old enough to remember those claims circa 1999-2000 as P/E’s soared to ridiculous heights. Back then, it was “The internet will change EVERYTHING!”. By that, the optimists meant that within a very few years, tech companies would find ways to make huge and ever-growing profits from the internet. Although the internet steadily became a more important part of life, the rapid, huge monetization did not happen, and so the stock market crashed in 2000 and took around ten years to recover.
A big reason for the lack of early monetization was the lack of exclusive “moats” around the early internet businesses. Pets.com was doomed from the start, because anyone could also slap together a competing site to sell dog food over the internet. The companies that are now reaping huge profits from the internet are those like Google and Meta (Facebook) and Amazon that have established quasi-monopolies in their niches.
The current mantra is, “Artificial intelligence will change EVERYTHING!” It is interesting to note that the same challenge to monetization is evident. ChatGPT cannot make a profit because customers are not willing to pay big for its chatbot, when there are multiple competing chatbots giving away their services for practically free. Again, no moat, at least at this level of AI. (If Zuck succeeds in developing agentic AI that can displace expensive software engineers, companies may pay Meta bigly for the glorious ability to lay off their employees).
My reaction to this dire ten-year prognostication is two-fold. First, I have a relatively high fraction of my portfolio in securities which simply pump out cash. I have written about these here and here. With these investments, I don’t much care what stock prices do, since I am not relying on some greater fool to pay me a higher price for my shares than I paid. All I care is that those dividends keep rolling in.
My other reaction is…this time it may be different (!), for the following reason: a huge fraction of the S&P 500 valuation is now occupied by the big tech companies. Unlike in 2000, these companies are actually making money, gobs of money, and more money every year. It is common, and indeed rational, to value (on a P/E basis) firms with growing profits more highly than firms with stagnant earnings. Yes, Nvidia has a really high P/E of 43, but its price to earnings-growth (PEG) ratio is about 1.2, which is actually pretty low for a growth company.
So, with a reasonable chunk of my portfolio, I will continue to party like it’s 1999.
[1] Here is a blurb from the Llama 3.1 chatbot offered for free in my Brave browser, summarizing the muted market outlook:
Financial institutions are forecasting lower stock market returns over the next decade compared to recent historical performance. According to Schwab’s 2025 Long-Term Capital Market Expectations, U.S. large cap equities are expected to deliver annualized returns of 6% over the next decade, while international developed market equities are projected to slightly outperform at 7.1%.1 However, Goldman Sachs predicts a more modest outlook, with the S&P 500 expected to return around 3% annually over the next decade, within a range of –1% and 7%.42 Vanguard’s forecasts also indicate a decline in expected returns, with U.S. equities falling to a range of 2.8% to 4.8% annually. These forecasts suggest that investors may face a period of lower returns compared to the past decade’s 13% annualized total return.
Anyone not living under a rock the last two weeks has heard of DeepSeek, the cheap Chinese knock-off of ChatGPT that was supposedly trained using much lower resources that most American Artificial Intelligence efforts have been using. The bearish narrative flowing from this is that AI users will be able to get along with far fewer of Nvidia’s expensive, powerful chips, and so Nvidia sales and profit margins will sag.
The stock market seems to be agreeing with this story. The Nvidia share price crashed with a mighty crash last Monday, and it has continued to trend downward since then, with plenty of zig-zags.
I am not an expert in this area, but have done a bit of reading. There seems to be an emerging consensus that DeepSeek got to where it got to largely by using what was already developed by ChatGPT and similar prior models. For this and other reasons, the claim for fantastic savings in model training has been largely discounted. DeepSeek did do a nice job making use of limited chip resources, but those advances will be incorporated into everyone else’s models now.
Concerns remain regarding built-in bias and censorship to support the Chinese communist government’s point of view, and regarding the safety of user data kept on servers in China. Even apart from nefarious purposes for collecting user data, ChatGPT has apparently been very sloppy in protecting user information:
Wiz Research has identified a publicly accessible ClickHouse database belonging to DeepSeek, which allows full control over database operations, including the ability to access internal data. The exposure includes over a million lines of log streams containing chat history, secret keys, backend details, and other highly sensitive information.
Shifting focus to Nvidia – – my take is that DeepSeek will have little impact on its sales. The bullish narrative is that the more efficient algos developed by DeepSeek will enable more players to enter the AI arena.
The big power users like Meta and Amazon and Google have moved beyond limited chatbots like ChatGPT or DeepSeek. They are aiming beyond “AI” to “AGI” (Artificial General Intelligence), that matches or surpasses human cognitive capabilities across a wide range of cognitive tasks. Zuck plans to replace mid-level software engineers at Meta with code-bots before the year is out.
For AGI they will still need gobs of high-end chips, and these companies show no signs of throttling back their efforts. Nvidia remains sold out through the end of 2025. I suspect that when the company reports earnings on Feb 26, it will continue to demonstrate high profits and project high earnings growth.
Its price to earnings is higher than its peers, but that appears to be justified by its earnings growth. For a growth stock, a key metric is price/earnings-growth (PEG), and by that standard, Nvidia looks downright cheap:
How the fickle market will react to these realities, I have no idea.
The high volatility in the stock makes for high options premiums. I have been selling puts and covered calls to capture roughly 20% yields, at the expense of missing out on any rise in share price from here.
Disclaimer: Nothing here should be considered as advice to buy or sell any security.
The biggest single-day decline in stock market history occurred yesterday, as Nvidia plunged 17% to shave $589 billion off the AI chipmaker’s market cap. The cause of the panic was the surprisingly good performance of DeepSeek, a new Chinese AI application similar to ChatGPT.
Those who have tested DeepSeek find it to perform about as well as the best American AI models, with lower consumption of computer resources. It is also available much cheaper. What really stunned the tech world is that the developers claimed to have trained the model for only about six million dollars, which is way, way less than the billions that a large U.S. firm like OpenAI, Google, or Meta would spend on a leading AI model. All this despite the attempts by the U.S. to deny China the most advanced Nvidia chips. The developers of DeepSeek claim they worked with a modest number of chips, models with deliberately curtailed capacities which met U.S. export allowances.
One conclusion, drawn by the Nvidia bears, is that this shows you *don’t* need ever more of the most powerful and expensive chips to get good development done. The U.S. AI development model has been to build more, huge, power-hungry data centers and fill them up with the latest Nvidia chips. That has allowed Nvidia to charge huge profit premiums, as Google and other big tech companies slurp up all the chips that Nvidia can produce. If that supply/demand paradigm breaks, Nvidia’s profits could easily drop in half, e.g., from 60+% gross margins to a more normal (but still great) 30% margin.
The Nvidia bulls, on the other hand, claim that more efficient models will lead to even more usage of AI, and thus increase the demand for computing hardware – – a cyber instance of Jevons’ Paradox (where the increase in the efficiency of steam engines in burning coal led to more, not less, coal consumption, because it made steam engines more ubiquitous).
I read a bunch of articles to try to sort out hype from fact here. Folks who have tested DeepSeek find it to be as good as ChatGPT, and occasionally better. It can explain its reasoning explicitly, which can be helpful. It is open source, which I think means the code or at least the “weights” have been published. It does seem to be unusually efficient. Westerners have downloaded it onto (powerful) PCs and have run it there successfully, if a bit slowly. This means you can embed it in your own specialized code, or do your AI apart from the prying eyes of ChatGPT or other U.S. AI providers. In contrast, ChatGPT I think can only be run on a powerful remote server.
Unsurprisingly, in the past two weeks DeepSeek has been the most-uploaded free app, surpassing ChatGPT.
It turns out that being starved of computing power led the Chinese team to think their way to several important innovations that make much better use of computing. See here and here for gentle technical discussions of how they did that. Some of it involved hardware-ish things like improved memory management. Another key factor is they figured out a way to only do training on data which is relevant to the training query, instead of training each time on the entire universe of text.
A number of experts scoff at the claimed six million dollar figure for training, noting that if you include all the costs that were surely involved in the development cycle, it can’t be less than hundreds of millions of dollars. That said, it was still appreciably cheaper than the usual American way. Furthermore, it seems quite likely that making use of answers generated by ChatGPT helped DeepSeek to rapidly emulate ChatGPT’s performance. It is one thing to catch up to ChatGPT; it may be tougher to surpass it. Also, presumably the compute-efficient tricks devised by the DeepSeek team will now be applied in the West, as well. And there is speculation that DeepSeek actually has use of thousands of the advanced Nvidia chips, but they hide that fact since it involved end-running U.S. export restrictions. If so, then their accomplishment would be less amazing.
What happens now? I wish I knew. (I sold some Nvidia stock today, only to buy it back when it started to recover in after-hours trading). DeepSeek has Chinese censorship built into it. If you use DeepSeek, your information gets stored on servers in China, the better to serve the purposes of the government there.
Ironically, before this DeepSeek story broke, I was planning to write a post here this week pondering the business case for AI. For all the breathless hype about how AI will transform everything, it seems little money has been made except for Nvidia. Nvidia has been selling picks and shovels to the gold miners, but the gold miners themselves seem to have little to show for the billions and billions of dollars they are pouring into AI. A problem may be that there is not much of a moat here – – if lots of different tech groups can readily cobble together decent AI models, who will pay money to use them? Already, it is being given away for free in many cases. We shall see…
As most of us know, artificial intelligence (AI) has taken big steps forward in the past few years, with the advent of Large Language Models (LLM) like ChatGPT. With these programs, you can enter a query in plain language, and get a lengthy response in human-like prose. You can have ChatGPT write a computer program or a whole essay for you (which of course makes it challenging for professors to evaluate essays handed in by their students).
However, the lords of Big Tech are not content. Their goal is to create AI with powers that far surpass human intelligence, and that even mimics human empathy. This raises a number of questions:
Is this technically possible? What will be the consequences if some corporations or nations succeed in owning such powerful systems? Will the computers push us bumbling humans out of the way? Will this be a tool for liberation or for oppression? This new technology coming at us may affect us all in unexpected ways.
For those who are interested, there will be a 75-minute webinar on Saturday, January 25 which addresses these issues, and offers a perspective by two women who are leaders in the AI field (see bios below). They will explore the ethical and practical aspects of AI of the future, from within a Christian tradition. The webinar is free, but requires pre-registration:
Joanna Ng is a former IBM-er, pivoted to a start-up founder, focusing on Artificial Intelligence, specialized in Augmented Cognition, by integrating with IoT and Blockchain, in the context of web3, by applying design-thinking methodology. With forty-nine patents granted to her name, Joanna was accredited as an IBM Master Inventor. She held a seven-year tenure as the Head of Research, Director of the Center for Advanced Studies, IBM Canada. She has published over twenty peer-reviewed academic publications and co-authored two computer science books with Springer, The Smart Internet, and The Personal Web. She published a Christianity Today article called “How Artificial Intelligence Is Today’s Tower of Babel” and published her first book on faith and discipleship in October 2022, titled Being Christian 2.0.
Rosalind Picard is founder and director of the Affective Computing Research Group at the MIT Media Laboratory; co-founder of Affectiva, which provides Emotion AI; and co-founder and chief scientist of Empatica, which provides the first FDA-cleared smartwatch to detect seizures. Picard is author of over three hundred peer-reviewed articles spanning AI, affective computing, and medicine. She is known internationally for writing the book, Affective Computing, which helped launch the field by that name, and she is a popular speaker, with a TED talk receiving ~1.9 million views. Picard is a fellow of the IEEE and the AAAC, and a member of the National Academy of Engineering. She holds a Bachelors in Electrical Engineering from Georgia Tech and a Masters and Doctorate, each in Electrical Engineering and Computer Science, from MIT. Picard leads a team of researchers developing AI/machine learning and analytics to advance basic science as well as to improve human health and well-being, and has served as MIT’s faculty chair of their MindHandHeart well-being initiative.
Economist Writing Every Day 
